Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance
about
Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinasesMnk kinase pathway: Cellular functions and biological outcomesEffective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitorTargeting the translational machinery as a novel treatment strategy for hematologic malignanciesSimultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells.Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development.Extensive gene-specific translational reprogramming in a model of B cell differentiation and Abl-dependent transformationA novel Bcr-Abl-mTOR-eIF4A axis regulates IRES-mediated translation of LEF-1Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.Inhibition of Mitogen-activated Protein Kinase (MAPK)-interacting Kinase (MNK) Preferentially Affects Translation of mRNAs Containing Both a 5'-Terminal Cap and Hairpin.The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia.The oncogene eIF4E: using biochemical insights to target cancer.Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell functionDiscovery of a BTK/MNK dual inhibitor for lymphoma and leukemiaCGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.BCR-ABL1 kinase-dependent alteration of mRNA metabolism: potential alternatives for therapeutic intervention.Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL.The biological and therapeutic relevance of mRNA translation in cancer.Attacking a nexus of the oncogenic circuitry by reversing aberrant eIF4F-mediated translation.Eukaryotic translation initiation factor 4E as a novel therapeutic target in hematological malignancies and beyond.Targeting translation: eIF4E as an emerging anticancer drug target.Unveiling new chemical scaffolds as Mnk inhibitors.Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.Coexpression Pattern Analysis of NPM1-Associated Genes in Chronic Myelogenous Leukemia.Ribosomal protein S6 phosphorylation is controlled by TOR and modulated by PKA in Candida albicans.Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming.Phosphorylated ribosomal protein S6 correlation with p21 expression and inverse association with tumor size in oral squamous cell carcinoma.Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia.
P2860
Q24632768-7D39D845-2166-4973-AA74-880BE6839B26Q26865459-3F1E6FA0-E215-4A4D-99A1-23A44393EDEBQ33597663-1C1F3D5B-DC5A-49CC-85BA-70138D5E0883Q33747291-A9B87475-CC93-41D9-9CE8-978DFF1BB1D6Q34031521-8057FC70-55BF-47CD-9371-2F83E3728E57Q34069663-9FA35D5E-5AE1-429A-97A0-165984E401C0Q34302309-B761B2E4-AF8D-464E-A9A5-5E70104C4994Q34589167-BA693DE7-14C0-4D16-A242-53235264B86FQ35758763-B037470E-184D-4AC4-8B53-DE8DDF733125Q36573991-07C247EC-FD68-4499-9F41-92DCF0E2B721Q36771927-E106DA1C-F6E8-4171-883C-848A7F8B1E97Q36842143-2B2C15E6-0B8C-4D1C-BFAC-0775C83C884BQ36950337-8085F043-F1BF-4740-881C-B3E976B008FAQ37180382-B61F4ED5-2876-46C0-BDBF-773487680E84Q37317400-174F0632-52D2-4B83-AA46-D52B882F5D37Q37836928-85C3FEDA-3BD0-44D8-BFBF-5ECCC464B42FQ37836931-DAE80310-7CA7-47BC-A54F-B9A3D9BBB056Q37848652-0C0D1489-568A-476D-9A49-AA5BE01D445BQ38008847-2A81D533-250F-406F-94B8-6C89382AD1DBQ38227377-CDD5F4C6-BBEE-4569-856B-6C80E6E94073Q38699320-0F70674A-3B1B-4FFC-9EE2-A684EB65A13CQ38791406-78819E72-D818-4D53-96B8-75ACB61FBC73Q39010703-F486A83F-A5FC-45A3-801E-F84913A4ED06Q40031374-F0A7936F-C56F-4957-B6DD-C6DA21011050Q41109006-D16B52F9-227E-4024-8C41-A9A2CC27F1D7Q41947180-B4E669CD-E30A-4DEC-B6EB-E80B9EB6AECDQ47202432-FC24D10F-759F-4539-B3B4-B8918AA88FA9Q48057652-B841A094-45FA-4DD8-A0D2-A8193F18EB2B
P2860
Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Inhibition of polysome assembl ...... overcomes imatinib resistance
@en
type
label
Inhibition of polysome assembl ...... overcomes imatinib resistance
@en
prefLabel
Inhibition of polysome assembl ...... overcomes imatinib resistance
@en
P2093
P2860
P356
P1476
Inhibition of polysome assembl ...... overcomes imatinib resistance
@en
P2093
Hermann Gram
Hung Y Fan
James C Moore
John Fruehauf
Jung Woo Kim
Sharmila Prabhu
Valerie Trapp
P2860
P304
P356
10.1128/MCB.00477-08
P407
P577
2008-08-11T00:00:00Z